[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"letrozole\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:letrozole":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100544686","letrozole-stimulated-cycle-strategy-versus-artificial-cycle-strategy-letsact-100544686",false,"NCT06372119","Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)","Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy for Endometrial Preparation in Women With Irregular Menstrual Cycles: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged between 18 - 42.\n* Irregular menstrual cycle (\\\u003C 21 days or \\> 35 days or \\\u003C 8 cycles\u002Fyears).\n* Indicated for endometrial preparation.\n* Transfer of only one blastocyst.\n* Not participating in any other trials.\n\nExclusion Criteria:\n\n* Allergy to letrozole or Ovitrelle or oral estradiol valerate or micronized progesterone\n* Having embryos from either oocyte donation or PGT (pre-implantation genetics testings) cycles.\n* Ovarian cysts that are unrelated to the oocyte pick-up.\n* Confirmed diagnosis with recurrent pregnancy loss (RPL) according to ESHRE guideline 2023, recurrent implantation failure (RIF) according to ESHRE 2023 good practice recommendations.\n* Endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, and chronic endometritis.\n* Uterine abnormalities include leiomyomas L0, L1, or L2 (according to FIGO 2011); adenomyosis (according to MUSA 2022); congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate (according to ASRM 2021).\n* Untreated hydrosalpinx.",true,"FEMALE","18 Years","42 Years",{"count":21,"type":22},790,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this randomized clinical trial is to evaluate the effectiveness of the letrozole-stimulated cycle strategy versus the artificial cycle strategy for endometrial preparation in women with irregular menstrual cycles after one cycle of endometrial preparation. The primary question it aims to answer is:\n\n• Does the letrozole-stimulated cycle strategy for endometrial preparation result in a higher live birth rate compared to the artificial cycle strategy in women with irregular menstrual cycles after one cycle of endometrial preparation?\n\nParticipants will undergo screening before endometrial preparation for frozen embryo transfer, following which they will be randomly assigned to one of two groups: LETS or AC. In the LETS group, investigators will prescribe letrozole 5 milligrams\u002Fday for 5 days to stimulate follicular development and micronized progesterone 800 milligrams\u002Fday for luteal phase support. In contrast, the AC group will receive oral estradiol valerate 6-12 milligrams\u002Fday and micronized progesterone 800 milligrams\u002Fday. Researchers will compare the LETS and AC groups to determine if there are differences in live birth rates.",[28,29,30,31],"Embryo Transfer","Irregular Menstruation","Letrozole","Hormone Replacement Therapy",[33,29,30,31],"Blastocyst Transfer","RECRUITING","2025-09-22",{"date":37,"type":38},"2025-09-25","ACTUAL",{"date":40,"type":38},"2024-04-22",{"date":42,"type":22},"2026-04",{"name":44,"class":45},"Mỹ Đức Hospital","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100587930","le--cc-vs-le-for-ovulation-induction-100587930","NCT06934785","LE + CC vs. LE for Ovulation Induction","The Combination of Letrozole (LE) and Clomiphene Citrate (CC) or LE Alone for Ovulation Induction in Women With WHO Group II\u002FIV Ovulatory Disorders: A Randomized Controlled Trial","COLA","Inclusion Criteria:\n\n* Women 18-40 years of age\n* Having WHO II\u002FIV ovulatory disorders (length of cycle \\\u003C 21 or \\> 35 days or having \\\u003C 8 cycles per year)\n* Progressive motility (PR) ≥ 32%, sperm concentration ≥ 5 million\u002Fml, total progressive motility sperm count \\> 5 million (World Health Organization, 2021)\n* Written informed consent.\n* Not participating in other studies.\n\nExclusion Criteria:\n\n* Untreated thyroid disease; Thyroid disease is suspected if patients have one of these (Bednarczuk et al., 2021); TSH ≥4 mIU\u002FL or TSH ≥2.5mIU\u002FL and TPOAb (+) or TSH \\\u003C0.1mIU\u002FL\n* Untreated hyper-prolactinemia; Hyperprolactinemia is suspected if patients have prolactinemia concentration \\>50 ng\u002FmL (The sample is collected after an overnight fast, at least 2 hours after waking up, ensuring that venipuncture does not cause excessive stress.)\n* Allergy or having contraindications to LE or CC;\n* Unilateral or Bilateral fallopian tube blockage (HSG, HyFoSy or surgery confirmation)\n* Untreated endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, or chronic endometritis.\n* Uterine abnormalities include leiomyomas L0, L1, or L2; severe adenomyosis; congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate.","40 Years",{"count":57,"type":22},600,[25],"This randomized controlled trial (RCT) aims to evaluate whether, in infertile women with WHO II\u002FIV ovulatory disorders, a combination of letrozole (LE) and clomiphene citrate (CC) compared to LE alone, result in higher live birth rates.\n\nThe study is designed as an open-label, multicenter RCT across six fertility clinics in Vietnam. Participants will be randomized into two groups: (1) LE + CC , (2) LE alone. The primary outcome measure is the live birth rate after one treatment cycle. Based on prior data, the live birth rate for IUI in letrozole cycles is estimated at 12%. To detect a 10% increase in live birth rates with CC, 436 couples are needed (α = 0.05, power = 80%). Additionally, the live birth rate after IUI with LE-induced ovulation is approximately 18.7% (Diamond et al., 2015). To detect a 10% increase with CC, 560 couples are required (α = 0.05, power = 80%). Considering a 5% loss to follow-up and protocol deviations, the study plans to recruit 600 participants (150 per arm).",[30,61,62,63],"Clomiphene Citrate","Ovulation Disorder","Ovulation Induction","2025-09-04",{"date":66,"type":38},"2025-09-11",{"date":68,"type":38},"2025-04-28",{"date":70,"type":22},"2027-06-30",{"name":44,"class":45},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":55,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":72},"100516559","the-effectiveness-of-the-letrozole-induced-endometrial-preparation-protocol-in-frozen-thawed-embryo-transfer-fet-100516559","NCT06006091","The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)","Clinical Outcomes of Letrozole-induced Endometrial Preparation Regimens Versus Conventional Endometrial Preparation Regimens Including Natural Cycle, Hormone Replacement Regimens in FET, a Randomized Controlled Study","Inclusion Criteria:\n\nWomen \\\u003C40 years of age undergoing IVF or ICSI at our reproductive center with a total of ≤3 superovulation cycles , and with ≥2 cleavage embryos or ≥1 blastocyst were cryopreserved. Previous cycles of embryo transfer ≤ 2 and only one transfer cycle with 1-2 embryos per study subject was enrolled.\n\nExclusion Criteria:\n\n1. Patients with chromosomal abnormalities in either spouse, hydrosalpinx, severe endometriosis, adenomyosis, and uterine and uterine cavity organic diseases such as uterine malformations, endometrial polyps, and uterine adhesions;\n2. patients who underwent pre-implantation genetic diagnosis (PGT);\n3. patients who underwent ICSI using surgically obtained epididymal or testicular spermatozoa;\n4. patients with a Body mass index (BMI, = weight\u002Fheight2 ) \\> 30 kg\u002Fm2;\n5. patients with recurrent spontaneous abortions;\n6. patients with sequential embryo transfer.",{"count":81,"type":22},858,[25],"The goal of this single center, non-blinded, randomized controlled clinical trial to comparison of pregnancy outcomes and perinatal outcomes in patients undergoing IVF treatment (including ICSI) with FET with letrozole-induce endothelial preparation protocol versus natural cycles, hormone replacement protocol.\n\nThe main questions it aims to answer are:\n\n* To investigate whether letrozole-induce endothelial preparation is effective in improving the live birth rate and clinical pregnancy rate.\n* To explore its possible impact on clinically important indicators such as spontaneous abortion rate, implantation cycle cancellation rate, days of endothelial preparation, and number of visits to the clinic.\n\nThe study subjects were randomized into groups starting at D1-D3 of the menstrual cycle. The study subjects were stratified according to whether their menstrual cycles were regular or not, and were divided into the following endothelial preparation regimens according to the pre-prepared stratified zoned randomized group numbers: (1) regular menstrual cycles (25-35 d): letrozole ovulation-promoting cycles, natural cycles, and hormone-replacement cycles; and (2) irregular menstrual cycles (\\\u003C25 d or \\>35 d): letrozole ovulation-promoting cycles, hormone-replacement cycle.",[30,85],"Infertility, Female",[87,88,89],"Frozen-thawed embryo transfer","Letroziole","Endothelial preparation protocol","2023-08-16",{"date":92,"type":38},"2023-08-23",{"date":94,"type":38},"2023-08-01",{"date":96,"type":22},"2027-08-01",{"name":98,"class":45},"International Peace Maternity and Child Health Hospital"]